Kancera AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
05-16 | Kancera AB Provides Operational Update Regarding the Kandova Study and Reports Increased Patient Recruitment | CI |
05-08 | Kancera AB Announces Executive Changes | CI |
Sales 2024 * | - | Sales 2025 * | 68.9M 6.54M 514M | Capitalization | 210M 19.95M 1.57B |
---|---|---|---|---|---|
Net income 2024 * | -68M -6.46M -507M | Net income 2025 * | 53M 5.03M 396M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.05 x |
P/E ratio 2024 * |
-2.89
x | P/E ratio 2025 * |
4.34
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 45.56% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Selin
CEO | Chief Executive Officer | - | 28/02/22 |
Director of Finance/CFO | 75 | - | |
Johan Schultz
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 04/05/10 | |
Director/Board Member | 66 | 31/12/15 | |
Håkan Mellstedt
FOU | Founder | 82 | 27/04/10 |
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |